2-(2,6-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid | 594839-89-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(2,6-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid
• 英文别名: 2-(2,6-dichlorophenyl)benzo[d]oxazole-6-carboxylic acid；2-(2,6-dichloro-phenyl)-benzooxazole-6-carboxylic acid
• CAS: 594839-89-1
• 化学式: C₁₄H₇Cl₂NO₃
• 分子量: 308.12
• InChiKey: XVNRKPCHMYOPPL-UHFFFAOYSA-N

物化性质

• 沸点：
  479.1±40.0 °C(Predicted)
• 密度：
  1.530±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(2,6-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid 在 盐酸 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 生成 C₁₈H₁₅Cl₂N₃O₂*ClH
  参考文献：
  名称：

  Brain Permeable Tafamidis Amide Analogs for Stabilizing TTR and Reducing APP Cleavage

  摘要：

  Tafamidis, 1, a potent transthyretin kinetic stabilizer, weakly inhibits the gamma-secretase enzyme in vitro. We have synthesized four amide derivatives of 1. These compounds reduce production of the A beta peptide in N2a695 cells but do not inhibit the gamma-secretase enzyme in cell-free assays. By performing fluorescence correlation spectroscopy, we have shown that TTR inhibits A beta oligomerization and that addition of tafamidis or its amide derivative does not affect TTR's ability to inhibit A beta oligomerization. The piperazine amide derivative of tafamidis (1a) efficiently penetrates and accumulates in mouse brain and undergoes proteolysis under physiological conditions in mice to produce tafamidis.

  DOI：

  10.1021/acsmedchemlett.9b00688
• 作为产物：
  描述：

  2-(2,6-dichlorophenyl)-benzooxazole-6-carboxylic acid methyl ester 在 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 生成 2-(2,6-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid
  参考文献：
  名称：

  苯并恶唑作为运甲状腺素蛋白淀粉样蛋白原纤维抑制剂：合成，评估和作用机理。

  摘要：

  DOI：

  10.1002/anie.200351179

文献信息

• ORGANIC COMPOUNDS
  申请人：Sung Moo Je

  公开号：US20110046133A1

  公开（公告）日：2011-02-24

  The present invention provides compounds of the following structure; A-L1-B-C-D that are useful for treating or preventing conditions or disorders associated with DGAT1 activity in animals, particularly humans.

  本发明提供了以下结构的化合物；A-L1-B-C-D，这些化合物对于治疗或预防与动物（尤其是人类）中DGAT1活性相关的疾病或疾病非常有用。
• METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES
  申请人：KELLY Jeffery W.

  公开号：US20120065237A1

  公开（公告）日：2012-03-15

  Kinetic stabilization of the native state of transthyretin is an effective mechanism for preventing protein misfolding. Because transthyretin misfolding plays an important role in transthyretin amyloid diseases, inhibiting such misfolding can be used as an effective treatment or prophylaxis for such diseases. Treatment methods are disclosed.

  动力学稳定化甲状腺素转运蛋白的天然状态是防止蛋白质错误折叠的有效机制。因为甲状腺素转运蛋白的错误折叠在甲状腺素转运蛋白淀粉样疾病中扮演重要角色，抑制这种错误折叠可以用作有效的治疗或预防这种疾病的方法。本文公开了治疗方法。
• Methods for treating transthyretin amyloid diseases
  申请人：Kelly W. Jeffery

  公开号：US20070078186A1

  公开（公告）日：2007-04-05

  Kinetic stabilization of the native state of transthyretin is an effective mechanism for preventing protein misfolding. Because transthyretin misfolding plays an important role in transthyretin amyloid diseases, inhibiting such misfolding can be used as an effective treatment or prophylaxis for such diseases. Treatment methods are disclosed.

  转甲状腺素原生态稳定化是预防蛋白质错构的有效机制，因为转甲状腺素的错构在转甲状腺素淀粉样病中扮演着重要角色，抑制此类错构可用作该类疾病的有效治疗或预防。披露了治疗方法。
• METHOD OF TREATMENT
  申请人：Bose Avirup

  公开号：US20100016387A1

  公开（公告）日：2010-01-21

  Method of preventing or treating myocardial ischemia by inhibiting DGAT1 enzyme with a DGAT1 inhibitor compound.

  通过使用DGAT1抑制剂化合物来抑制DGAT1酶，预防或治疗心肌缺血的方法。
• Organic compounds
  申请人：Novartis AG

  公开号：US08222248B2

  公开（公告）日：2012-07-17

  The present invention provides compounds of the following structure; A-L1-B—C-D that are useful for treating or preventing conditions or disorders associated with DGAT1 activity in animals, particularly humans.

  本发明提供了以下结构的化合物；A-L1-B—C-D，用于治疗或预防与动物，特别是人类DGAT1活性相关的病症或疾病。